Vertex Remains On Track With Telaprevir For 2010 NDA, 2011 Anticipated Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Looking to be the leader in STAT-C combo therapy for hepatitis C, Vertex also plans trial testing telaprevir with VX-222.
You may also be interested in...
Vertex Advances Toward Telaprevir Approval
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.
Vertex Advances Toward Telaprevir Approval
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.
Prospect Of Predictive Gene Test Grips Developers Of Hepatitis C Drugs
The discovery of a gene marker that foretells the effectiveness of current standard-of-care therapy in hepatitis C offers a new tool for drug development and a potential guide for clinicians